Monogram Orthopaedics Inc ( (MGRM) ) has released its Q2 earnings. Here is a breakdown of the information Monogram Orthopaedics Inc presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Monogram Technologies Inc., an AI-driven robotics company focused on orthopedic surgery, is developing advanced surgical robots and related technologies to improve human health. The company recently announced a significant merger agreement with Zimmer Biomet Holdings, Inc., which will see Monogram become a wholly-owned subsidiary of Zimmer Biomet. Key financial highlights from the latest earnings report reveal a net loss of $8.6 million for the first half of 2025, with operating expenses totaling $6.4 million. Despite the losses, Monogram has secured FDA clearance for its mBôs™ TKA System, marking a critical milestone in its product development. Looking ahead, the merger with Zimmer Biomet is expected to provide Monogram with additional resources and support, positioning the company for potential growth and expansion in the orthopedic sector.